On April 28, 2015, FDA conducted a public meeting on Chagas Disease Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of chagas disease on daily life and patients’ views on currently available therapies to treat the condition. FDA is also interested in discussing issues related to scientific challenges in developing drugs to treat Chagas disease. In the afternoon, FDA will provide information for and gain perspective from patients and patient advocacy organizations, health care providers, academic experts, and industry on various aspects of clinical development of drug products intended to treat Chagas disease.
This website will be updated as meeting materials are developed.
April 28, 2015
9:00 a.m. to 5:00 p.m.
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A (Great Room)
Silver Spring, MD 20993
Enter at Building 1 to clear security
(Information about arrival to FDA’s White Oak campus)
To register for this meeting, visit: Registration information
Registration will close on April 10, 2015
Submitting comments to the public docket:
In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 29, 2015.
Chagas Disease Meeting Agenda, April 28, 2015(PDF - 153KB)
- Chagas Disease Meeting Slides (PDF - 12.3MB)
Chagas Disease Meeting Slides (Spanish)(PDF - 1.2MB) Webinar: Background on FDA and Patient-Focused Drug Development[ARCHIVED] Flyer for Chagas Disease Patient-Focused Drug Development Meeting(PDF - 111KB) Chagas Disease Meeting Questions (Spanish)(PDF - 100KB)
- Chagas Disease Meeting Transcript (PDF - 3.7MB)
The Voice of the Patient: Chagas Disease(PDF - 311KB)